ANN ARBOR—ENDRA Life Sciences Inc., developers of thermo acoustic enhanced ultrasound technology for medical diagnosis, announced it had received two new United States Patents—No. 11,456,518, for “Method for Manufacturing a Radio Frequency Applicator,” and No. 11,478,153, for “System for Monitoring Tissue Temperature.”
“We are pleased with the issuance of our 32nd and 33rd patents in the United States, which supports our strategy to develop optimized thermoacoustic imaging systems, and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs,” stated ENDRA’s Chairman and CEO Francois Michelon. “We continue to strengthen our intellectual property portfolio to protect our novel technology in key global markets. Our IP portfolio currently includes 56 patents issued globally.”
The ‘518 patent provides further intellectual property protection for our TAEUS platform related to its disruptive scanning approach. It covers a method for manufacturing a radio frequency applicator device that is used to provide reliable RF energy in a target region of tissue. Specifically, the ‘518 patent further defines ENDRA’s innovative solution to provide targeted RF energy to tissue regions for certain applications, such as fat quantification of a patient’s liver. The ‘518 patent is linked to its parent, U.S. Patent No. 10682059, which covers embodiments of the RF applicator device.
The ‘153 patent relates to the TAEUS system monitoring tissue temperature during surgical procedures. ENDRA expects its system to be effective for both thermotherapy and cryotherapy procedures. The ‘153 patent is linked to its parent, U.S. patent No. 10631734, which covers complementary method embodiments.
ENDRA’s TAEUS technology is being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.